Advertisement
Canada markets close in 6 hours 24 minutes
  • S&P/TSX

    21,929.57
    +44.19 (+0.20%)
     
  • S&P 500

    5,082.26
    +33.84 (+0.67%)
     
  • DOW

    38,134.38
    +48.58 (+0.13%)
     
  • CAD/USD

    0.7315
    -0.0008 (-0.11%)
     
  • CRUDE OIL

    84.33
    +0.76 (+0.91%)
     
  • Bitcoin CAD

    87,397.97
    +1,150.59 (+1.33%)
     
  • CMC Crypto 200

    1,379.88
    -16.66 (-1.19%)
     
  • GOLD FUTURES

    2,356.90
    +14.40 (+0.61%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.6710
    -0.0350 (-0.74%)
     
  • NASDAQ

    15,823.30
    +211.54 (+1.36%)
     
  • VOLATILITY

    15.48
    +0.11 (+0.72%)
     
  • FTSE

    8,122.22
    +43.36 (+0.54%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

3 Clinical Trials to Watch in the First Half of 2022

In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022. Which clinical results are you especially looking forward to seeing? Brian Orelli: Arena (NASDAQ: ARNA), the ticker there is A-R-N-A, it expects data from a phase 3 study of etrasimod in patients with ulcerative colitis.